x

Posted 20 December, 2021

TherapeuticsMD, Inc. appointed Mr. Hugh O'Dowd as new CEO

Nasdaq:TXMD appointed new Chief Executive Officer Mr. Hugh O'Dowd in a 8-K filed on 20 December, 2021.


  On December 14, 2021, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Mr. Hugh O'Dowd, the Company's President, as the Company's Chief Executive Officer, and on December 18, 2021, the Board appointed Mr. O'Dowd as a director.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of TherapeuticsMD, Inc.
Health Care/Life Sciences • Pharmaceuticals
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Market Cap
$27.9M
View Company Details
TherapeuticsMD, Inc. by TradingView
Relevant filing section
Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On December 14, 2021, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Mr. Hugh O'Dowd, the Company's President, as the Company's Chief Executive Officer, and on December 18, 2021, the Board appointed Mr. O'Dowd as a director. Mr. O'Dowd succeeds Mr. Robert G. Finizio as the Company's Chief Executive Officer; Mr. Finizio will continue to serve as Vice Chair of the Board.

Except pursuant to Mr. O'Dowd's existing employment agreement, dated August 3, 2021, which was filed as an exhibit to the Company's Current Report on Form 8-K on August 9, 2021 and is incorporated herein by reference, there are no arrangements or understandings between Mr. O'Dowd and any other person pursuant to which he was appointed as Chief Executive Officer or as a director of the Company and no family relationships between Mr. O'Dowd and any director or executive officer of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company's last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Mr. O'Dowd had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.

Mr. Finizio's separation as the Company's Chief Executive Officer is a termination without "Cause," as defined in that certain employment agreement, dated November 24, 2020, by and between Mr. Finizio and the Company, and Mr. Finizio will receive the separation benefits provided therein.